H2 Pharma Offloads Minority Interest To Private Equity
French Liquids Specialist Eyes Production Goal
H2 Pharma, which specializes in both generic and OTC liquid formulations, is looking to climb to the next level after receiving an equity investment from Ardian.
You may also be interested in...
Pfizer’s efforts to circumvent two US patents shielding Par’s Adrenalin (epinephrine) have again ended in failure, following a ruling by the US Court of Appeals for the Federal Circuit.
Mooted some time ago, the Medicare Part D Drug Rebate Rule and the Medicare Part B Most-Favored-Nation Model have now been finalized by US President Donald Trump. But US off-patent body the Association for Accessible Medicines feels “further action is necessary.”
Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.